Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) have been assigned a consensus recommendation of “Moderate Buy” from the eight ratings firms that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $32.80.

A number of equities analysts recently weighed in on GLUE shares. TD Cowen reaffirmed a “buy” rating on shares of Monte Rosa Therapeutics in a report on Wednesday, January 7th. Jefferies Financial Group reaffirmed a “buy” rating and set a $31.00 target price on shares of Monte Rosa Therapeutics in a research note on Wednesday, January 7th. Weiss Ratings reiterated a “sell (d)” rating on shares of Monte Rosa Therapeutics in a research report on Monday, December 29th. Zacks Research lowered shares of Monte Rosa Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 4th. Finally, Wall Street Zen cut shares of Monte Rosa Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 21st.

Insider Transactions at Monte Rosa Therapeutics

In other news, insider Edmund Dunn sold 25,164 shares of the business’s stock in a transaction dated Friday, February 27th. The shares were sold at an average price of $18.10, for a total transaction of $455,468.40. Following the completion of the sale, the insider owned 22,693 shares of the company’s stock, valued at $410,743.30. The trade was a 52.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Markus Warmuth sold 5,466 shares of the company’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $17.92, for a total transaction of $97,950.72. Following the transaction, the chief executive officer owned 613,471 shares of the company’s stock, valued at approximately $10,993,400.32. This trade represents a 0.88% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 36,771 shares of company stock valued at $693,692 in the last three months. Corporate insiders own 6.90% of the company’s stock.

Hedge Funds Weigh In On Monte Rosa Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in GLUE. AQR Capital Management LLC acquired a new stake in shares of Monte Rosa Therapeutics in the first quarter worth approximately $1,065,000. Goldman Sachs Group Inc. raised its stake in Monte Rosa Therapeutics by 122.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 356,112 shares of the company’s stock valued at $1,652,000 after purchasing an additional 196,238 shares during the last quarter. Acadian Asset Management LLC purchased a new position in Monte Rosa Therapeutics in the 1st quarter valued at $76,000. Geode Capital Management LLC lifted its holdings in Monte Rosa Therapeutics by 12.0% in the 2nd quarter. Geode Capital Management LLC now owns 1,124,160 shares of the company’s stock valued at $5,071,000 after purchasing an additional 120,098 shares in the last quarter. Finally, Intech Investment Management LLC boosted its stake in Monte Rosa Therapeutics by 35.4% during the 2nd quarter. Intech Investment Management LLC now owns 29,870 shares of the company’s stock worth $135,000 after purchasing an additional 7,808 shares during the last quarter. Hedge funds and other institutional investors own 79.96% of the company’s stock.

Monte Rosa Therapeutics Stock Performance

GLUE stock opened at $15.67 on Friday. Monte Rosa Therapeutics has a one year low of $3.50 and a one year high of $25.77. The firm’s fifty day moving average is $18.93 and its 200 day moving average is $15.13. The firm has a market cap of $1.25 billion, a PE ratio of -34.07 and a beta of 1.63.

Monte Rosa Therapeutics (NASDAQ:GLUE) last posted its earnings results on Tuesday, March 17th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.45) by ($0.10). Monte Rosa Therapeutics had a negative return on equity of 15.12% and a negative net margin of 31.23%.The firm had revenue of $2.78 million for the quarter, compared to analysts’ expectations of $17.09 million. Research analysts predict that Monte Rosa Therapeutics will post -1.49 earnings per share for the current fiscal year.

About Monte Rosa Therapeutics

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.